Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Featured Articles
(BioPharma Dive) Dec 5, 2018 - Like many a medical meeting, ASH showcased data that — while promising — also offers as many questions as answers. With another American Society of Hematology meeting in the books, the industry can take a minute to appreciate the notable advances seen in San Diego earlier this week. A new...
Read Article
(BioPharma Dive) Dec 5, 2018 - In drugmakers' quest to coax immune cells to attack cancer, two might turn out to be better than one. Recent advances in cancer therapeutics have centered on the might of the body's defenders to recognize and kill tumor cells. Seeking to help the immune system "see" cancers, researchers have turned to...
Read Article
Latest Articles
December 13, 2018
December 13, 2018
December 11, 2018
December 10, 2018
December 07, 2018
December 06, 2018
December 06, 2018
December 06, 2018
View More
News Commentary
Editor Image
09 Jul, 2018 | by Winston Wong, PharmD
The math is simple. Under the proposed agreement, we pay for all doses of the...
View Comment
Editor Image
05 Apr, 2018 | by Winston Wong, PharmD
From a payer perspective, the CMS approval for coverage means that...
View Comment
View More
OBR Blog
By Lynne Lederman, PhD As the 2018 American Society of Hematology (ASH) Annual Meeting continues, we focus on two... Read more
December 03, 2018
Six presentations were given today at the plenary session at the 2018 American Society of Hematology (ASH) Annual... Read more
December 03, 2018